CoreLab Partners, Inc., announced the opening of an office in Tokyo, Japan under the wholly owned subsidiary of CoreLab Partners Japan, K.K.
“We are pleased to announce the creation of our new subsidiary in Asia corresponding with the opening of an office in central Tokyo” said CoreLab Partners’ President and Chief Executive Officer, Dr. Mike Woehler. “This expanded presence is a natural extension of our geographic reach and global strategy to serve our growing base of multinational biopharma companies operating in the region and will complement our operational capability which was established in Shanghai, China over a decade ago” added Woehler.
CoreLab Partners currently has a business alliance in Japan with Suzuken Co. Ltd. which markets its cardiac safety services; this new presence is designed to further establish the global brand in the Pacific Rim and expand their full line of imaging sciences capabilities in Southeast Asia. “CoreLabs has been present in the region since 1999 and has conducted hundreds of drug development studies in both cardiac safety and imaging for a variety of sponsor partners. The addition of a local Regional Director and Business Development professional will allow CoreLab Partners to better service our client base by nurturing current relationships and opening up new markets for our full line of cardiac safety and imaging services” said Kevin Duffy, Vice President, Global Business Development.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Vabysmo Shows Significant Vision Improvement for Diabetic Macular Edema in Underrepresented Patients
October 22nd 2024Phase IV ELEVATUM trial results show that one year of treatment with Vabysmo significantly improved vision in underrepresented racial and ethnic groups with diabetic macular edema, supporting the drug's efficacy and safety across diverse populations.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Clesrovimab Shows Significant Reduction in RSV Infections, Hospitalizations in Infants
October 18th 2024Merck's investigational monoclonal antibody, clesrovimab, shows significant efficacy in reducing respiratory syncytial virus-related infections and hospitalizations in infants, with a favorable safety profile.